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Alessandra Frioni, Francesca Berlutti, Rosalba Paesano, and Piera Valenti
Abstract: Chlamydia trachomatis is an obligate, intracellular pathogen responsible for the most common sexually transmitted
bacterial disease worldwide, causing acute and chronic infections. The acute infection is susceptible to antibiotics, whereas the
chronic one needs prolonged therapies, thus increasing the risk of developing antibiotic resistance. Novel alternative therapies
are needed. The intracellular development of C. trachomatis requires essential nutrients, including iron. Iron-chelating drugs
inhibit C. trachomatis developmental cycle. Lactoferrin (Lf), a pleiotropic iron binding glycoprotein, could be a promising
candidate against C. trachomatis infection. Similarly to the efﬁcacy against other intracellular pathogens, bovine Lf (bLf) could
both interfere with C. trachomatis entry into epithelial cells and exert an anti-inﬂammatory activity. In vitro and in vivo effects of
bLf against C. trachomatis infectious and inﬂammatory process has been investigated. BLf inhibits C. trachomatis entry into host
cells when incubated with cell monolayers before or at the moment of the infection and down-regulates IL-6/IL-8 synthesized by
infected cells. Six out of 7 pregnant women asymptomatically infected by C. trachomatis, after 30 days of bLf intravaginal
administration, were negative for C. trachomatis and showed a decrease of cervical IL-6 levels. This is the ﬁrst time that the bLf
protective effect against C. trachomatis infection has been demonstrated.
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Résumé : Chlamydia trachomatis est un pathogène obligatoire, intracellulaire, responsable de la maladie transmise sexuellement
bactérienne la plus courante a` travers le monde, causant des infections aigües et chroniques. L’infection aigüe est sensible aux
antibiotiques, alors que l’infection chronique nécessite des thérapies prolongées, augmentant ainsi le risque de développer une
résistance aux antibiotiques. Des thérapies novatrices alternatives sont requises. Le développement intracellulaire de C. trachomatis
requiert des nutriments essentiels dont le fer. Lesmédicaments chélateurs du fer inhibent le cycle développemental de C. trachomatis.
La lactoferrine (Lf), une glycoprotéine pléiotropique qui lie le fer pourrait constituer un candidat prometteur pour contrer
l’infection par C. trachomatis. Similairement son efﬁcacité envers d’autres pathogènes intracellulaires, la Lf bovine (bLf) pourrait
interférer avec l’entrée de C. trachomatis a` l’intérieur des cellules épithéliales et exercer une activité anti-inﬂammatoire. Les effets
in vitro et in vivo de la bLf envers le processus infectieux et inﬂammatoire de C. trachomatis ont été examinés. La bLF inhibe l’entrée
de C. trachomatis dans les cellules hôtes lorsqu’elle est incubée avec des cellules en monocouches avant ou au moment de
l’infection, et elle régule a` la baisse l’IL-6 et l’IL-8 synthétisées par les cellules infectées. Six femmes enceintes asymptomatiques
sur 7, infectées par C. trachomatis, se révélaient négatives quant a` la présence de C. trachomatis après 30 jours d’administration
intravaginale de bLf, et elles présentaient une diminution des niveaux cervicaux d’IL-6. C’est la première fois que l’effet
protecteur de la bLf contre l’infection par C. trachomatis a été démontré. [Traduit par la Rédaction]
Mots-clés : Chlamydia trachomatis, lactoferrine bovine, infection, inﬂammation, IL-6.
Introduction
Chlamydia trachomatis, an obligate intracellular pathogen, is the
leading cause of sexually transmitted bacterial infections in the
world, with an estimated >131 million new cases per year (Newman
et al. 2015). Chlamydia trachomatis genital infection manifests in
women as cervicitis, salpingitis, and endometritis, and can prog-
ress leading to severe sequelae, such as pelvic inﬂammatory dis-
ease, ectopic pregnancy, and obstructive infertility (Shaw et al.
2011). Importantly, amajor concern with chlamydial genital infec-
tions is that approximately 80% of women are asymptomatic, thus
resulting in a reservoir for onwards transmission in the popula-
tion (Shaw et al. 2011).
Chlamydia trachomatis is characterized by a unique biphasic de-
velopmental cycle alternating between the extracellular infec-
tious bodies (elementary bodies, EBs), metabolically inactive, and
the intracellular non-infectious bodies (reticulate bodies, RBs), met-
abolically active. The EBs adhesion and entry into mucosal epithe-
lial cells initiate a signal transduction cascade of the host cell,
leading to the recruitment and reorganization of the actin cyto-
skeleton at the site of attachment. Following the fusion of EB-
containing endosomes, EBs develop into larger, metabolically
active but noninfectious RBs. Using ATP and nutrients from the
host cell, RBs grow and divide by binary ﬁssion within amembrane-
bound vacuole, termed inclusion. Subsequently, the RBs asynchro-
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nously transform into EBs, which are released, after approximately
48 h, from the host cell by lysis (Wyrick 2010; Bastidas et al. 2013).
In recent years, it has been demonstrated that C. trachomatis can
generate a persistent form during its developmental cycle as a
consequence of several stress-inducing factors (Wyrick 2010;
Di Pietro et al. 2013). As a result, normal RBs transform into en-
larged and morphologically aberrant RBs, thus stopping the pro-
duction of infectious EBs (Hogan et al. 2004; Wyrick 2010). In
particular, C. trachomatis enters into the persistence state in the
presence of iron-chelating drugs, which inhibit the developmen-
tal cycle and, hence, show its dependence on iron for the achieve-
ment of infectious cycle (Raulston 1997; Thompson and Carabeo
2011). In this regard, iron limitation in host cells has been shown
to be of the utmost importance for the growth and survival of
Chlamydia spp. (Raulston 1997; Al-Younes et al. 2001).
Following C. trachomatis infection, cervical epithelial cells pro-
duce several pro-inﬂammatory cytokines including TNF-, IL-1,
IL-6, and IL-8 that augment the cell inﬂammatory response, thus
inducing direct damage to genital tissues. Furthermore, IL-8, in
turn, recruits innate immune cells, which are abundant in the
genital mucosa and are able to further worsen chronic inﬂamma-
tion and tissue-damage of the reproductive system (Redgrove and
McLaughlin 2014).
Interestingly, during the infection/inﬂammation, IL-8 recruits
neutrophils that synthesize and secrete granules containing lac-
toferrin (Lf) (Masson et al. 1969).
Recently, a great interest in Lf, considered as a prominent com-
ponent of the ﬁrst-line defense of the host against infections and
inﬂammation, has been raised.
Lf, an 80 kDa iron-binding glycoprotein, is found in most body
ﬂuids including vaginal ﬂuid (Valore et al. 2002). Lf possesses sev-
eral biological functions, dependent and independent from its
iron-binding ability (Valenti and Antonini 2005). Among the bio-
logical properties related to its iron-withholding ability, Lf inhib-
its bacterial infections, whereas independently from iron chelation,
its high positive charge favors the binding tomicroorganisms and
(or) host cells, thus hindering the adhesion and entry into epithe-
lial cells (Valenti and Antonini 2005). In addition to these activi-
ties, Lf demonstrates potent anti-inﬂammatory activity, protecting
infected host cells from damages associated with pathological in-
ﬂammation. In particular, independently from its iron-binding
ability, Lf decreases the synthesis of proinﬂammatory cytokines
in infected epithelial cells (Berlutti et al. 2006; Puddu et al. 2011;
Valenti et al. 2011; Frioni et al. 2014).
Given the impact of asymptomatic chlamydial infection on dis-
ease outcomes and the multifunctional features of Lf, the aim of
our studywas to evaluate the effects of bovinemilk derived Lf (bLf)
on C. trachomatis infection and on the associated inﬂammatory
state, in vitro and in vivo.
Materials and methods
Chlamydia trachomatis strain and cell culture
Chlamydia trachomatis L2 strain 434/Bu (ATCC VR-902B) was ob-
tained from the American Type Culture Collection.
The human epithelial HeLa-229 cell line from cervix adenocar-
cinoma (ATCC CCL-2.1) was cultured at 37 °C in Dulbecco’s Modi-
ﬁed Eagle Medium (DMEM; Euroclone, Milan, Italy), supplemented
with 10% fetal calf serum (FCS; Euroclone), in a humidiﬁed atmo-
sphere with 5% CO2.
Propagation and titration of C. trachomatis
Elementary body (EB) aliquots of C. trachomatis L2 were stored at
−80 °C and propagated in HeLa-229 cells, grown in DMEM supple-
mented with 10% FCS, as previously described by Mastromarino
et al. (2014). The infectious titer was assessed by immunoﬂuores-
cence assay (IFA). Brieﬂy, HeLa-229 cells grown on glass coverslips
in 24-well plates were infected with 10-fold serial dilutions of bac-
terial stock, incubated for 48 h at 37 °C, ﬁxed with methanol and
stained with ﬂuorescein isothiocyanate-conjugated monoclonal
(FITC) antibody anti-C. trachomatis (MicroTrak, Trinity Biotech).
The total number of C. trachomatis inclusion forming units (IFUs)
was obtained by counting all ﬁelds using a ﬂuorescence micro-
scope (100× magniﬁcation).
Lactoferrin
Highly puriﬁed bovine milk derived lactoferrin (bLf) was kindly
provided by Morinaga Milk Industries Co., Ltd. (Tokyo, Japan). The
absence of bLf degradation fragments was checked by SDS–PAGE
stainedwith silver nitrate. Lactoferrin concentrationwas assessed
by UV spectroscopy on the basis of an extinction coefﬁcient of 15.1
(280 nm, 1% solution). The purity of bLf corresponded to about
98%, as also detected by high-performance liquid chromatography
(HPLC) analysis. The bLf iron saturation was about 20%, as de-
tected by optical spectroscopy at 468 nm on the basis of an extinc-
tion coefﬁcient of 0.54 (100% iron saturation). LPS contamination
of bLf, estimated by Limulus Amebocyte assay (LAL Pyrochrome
kit; PBI International, Milan, Italy), was 0.7 ± 0.06 ng/mg of bLf.
Before biological assays, bLf solution was sterilized by ﬁltration
using 0.2 mMillex HV at low protein retention (Millipore Corp.,
Bedford, Massachusetts, USA). In all experiments bLf was used at
non-cytotoxic concentrations corresponding to 100 g/mL.
Effects of bovine lactoferrin on infection of HeLa-229 cells
with C. trachomatis elementary bodies
Pre-incubation of bLf with C. trachomatis EBs
To detect the efﬁcacy of bLf against C. trachomatis, 25 000 EBs/mL,
corresponding to a multiplicity of infection (MOI) of 0.05, were
pre-incubated in DMEMwith FCS 2% (freshmedium), in the absence
or presence of bLf (100 g/mL), for 1 h or 3 h at 37 °C in humidiﬁed
atmosphere with 5% CO2. Subsequently, the C. trachomatis EBs sus-
pension was centrifuged at 30 000g for 15 min, and the superna-
tant was removed. The pellet containing C. trachomatis EBs was
suspended in fresh medium and used to infect a total of about 105
HeLa-229 cells. Brieﬂy, after 1 h, the cells were washed with phos-
phate buffer solution without Ca2+ and Mg2+ (PBS) to remove the
non-internalized C. trachomatis EBs and newly incubated in fresh
medium. After 48 h post infection (h.p.i.) at 37 °C in 5% CO2, the
total number of C. trachomatis IFU was determined by IFA.
Pre-incubation of bLf with HeLa-229 cells before the infection
with C. trachomatis EBs
HeLa-229 cells were pre-incubated in fresh medium in the ab-
sence or presence of bLf (100 g/mL). After 1 h or 3 h of incubation
at 37 °C in 5% CO2, bLf was removed by washing the cell monolay-
ers 3 times with PBS. Subsequently, HeLa-229 cells were infected
with C. trachomatis at a MOI of 0.05 as above described. After
48 h.p.i. at 37 °C in 5% CO2, the total number of C. trachomatis IFU
was determined by IFA.
bLf addition to HeLa-229 cells at the moment of infection with
C. trachomatis EBs
In this set of experiments, bLf was added to HeLa-229 cells at the
moment of infection. Brieﬂy, HeLa-229 cells were infected with
C. trachomatis at a MOI of 0.05 in the absence or presence of bLf
(100 g/mL). After 1 h at 37 °C in 5% CO2, the cells were washed
with PBS to remove the non-internalized C. trachomatis EBs, and
fresh medium was added. After 48 h.p.i at 37 °C and 5% CO2, the
total number of C. trachomatis IFU was determined by IFA.
bLf addition to HeLa-229 cells 3 h after C. trachomatis infection
HeLa-229 cells were infected with C. trachomatis at a MOI of 0.05.
After 1 h of incubation at 37 °C in 5% CO2, the cells were washed
with PBS to remove the non-internalized C. trachomatis EBs and
fresh medium was added. After further 3 h of incubation at 37 °C
in 5% CO2, fresh medium, with or without bLf (100 g/mL), was
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added to the infected cells. After 48 h.p.i. at 37 °C and 5% CO2, the
total number of C. trachomatis IFU was determined by IFA.
Detection of cytokines
Preliminary experiments, carried out with C. trachomatis EBs
at a MOI of 0.05, showed a very low cytokine expression by
infected HeLa-229 cells. Therefore, HeLa-229 cells were infected
with C. trachomatis EBs at a MOI of 5 to reach a higher expression
of IL-6 and IL-8 than that observed at the MOI of 0.05. After 1 h of
incubation, the cells were washed with PBS to remove the non-
internalized C. trachomatis EBs and supplemented with fresh me-
dium. After further 3 h of incubation at 37 °C in 5% CO2, fresh
medium, with or without bLf (100 g/mL), was added to the in-
fected cells. The cytokine production was determined in cell
monolayer supernatants by ELISA using Human ELISA Max De-
luxe Set (BioLegend, San Diego, California, USA) after 48 h of
incubation at 37 °C in 5% CO2.
Study design
We conducted an open-label cohort study in accordance with
the ethical principles of the Declaration of Helsinki. Approval was
granted by the Ethics Committee of Clinica Fabia Mater, Via Ol-
evano Romano, 25 Rome, Italy (FM MOD 26022010). All of the
pregnant women gave written informed consent.
One hundred ninety-eight pregnant women from 20 to 40 years
without ascertained pathologies, with normal uterine cavity, and
intact membranes were enrolled regardless of trimester. Women
were excluded if they had a pathological pregnancy or if during
this study they were affected by bacterial vaginal infections unre-
lated to C. trachomatis.
The exclusion of pregnant women during the clinical trial was
also considered on the basis of voluntary declaration, lack of treat-
ment effectiveness, side effects, protocol infringement, and missed
programmed visits. The enrolled pregnant women were on a
monthly scheduled visit.
Laboratory tests
At each scheduled visit, in addition to standard assays (haemat-
ocrit, glycemia, uricemia, bilirubin, glutamicoxaloacetic transami-
nase, glutamic pyruvic transaminase, cholesterol, triglyceride acid,
and electrolytes), cervical specimens were collected with polyeth-
ylene terephthalate (Dacron) swabs to detect the presence of
C. trachomatis. In addition, cervical ﬂuids were analyzed to detect
IL-6 concentrations.
Chlamydia trachomatis detection
Cervical specimens were analyzed by direct immunoﬂuores-
cence assay (DFA) using Syva Microtrack kit (Syva Microtrack;
Trinity Biotech) according to the manufacturer’s instructions.
Brieﬂy, the smears were ﬁxed with methanol and stained with
ﬂuorescein isothiocyanate conjugated (FITC) monoclonal anti-
body against C. trachomatis major outer membrane protein
(MOMP) for 30 min at 37 °C in a humid chamber. The slides were
examined for the presence of IFUs using ﬂuorescence microscope
(100× magniﬁcation).
Treatment against C. trachomatis infection in pregnant
women
Among 198 pregnant women, 7 women, asymptomatically af-
fected by C. trachomatis, were immediately treated with bLf intravag-
inal administration. The intravaginal tablet, containing 100 mg of
lyophilized bLf 20% iron-saturated, was administered every 8 h for
30 days. The tablets were administered through a vaginal applica-
tor to obtain a fast and adequate dissolution. If the treatment with
bLf intravaginal administration for 30 days was ineffective, the preg-
nant women were submitted to antibiotic therapy (Workowski and
Bolan 2015).
Maternal side effects
The side effects of bLf intravaginal administration were as-
sessed by monitoring vaginal irritation, itching, and burning.
Fetal and newborn side effects
Fetal vital sign assessments were monitored by ultrasono-
graphic measurements of intrauterine growth and through the
amount of amniotic ﬂuid, expressed as the amniotic ﬂuid index
(AFI). Newborn weight and Apgar score were registered. Apgar
score is a practical method of evaluating the physical condition of
a newborn shortly after delivery (Apgar 1953). An Apgar score of
0–3 at 5–10 min of age is predictive of high morbidity and mortal-
ity, while an Apgar score of 9–10 means the infant is in the best
possible conditions.
Statistical analysis
All values are the mean ± standard deviation (SD) of 3 replicates
from 3 independent in vitro experiments. The concentrations of
IL-6 in cervical ﬂuid of pregnant women were expressed as mean
values ± SD. Comparison of means was performed by using a
2-tailed t-test for independent samples. A value for P < 0.05 was
considered statistically signiﬁcant.
Results
Effects of bovine lactoferrin on C. trachomatis infection
We evaluated the effects of bLf, at non-cytotoxic concentration
corresponding to 100 g/mL on C. trachomatis infections.
As shown in Fig. 1A, no signiﬁcant reduction in the number of
chlamydial IFUs was observed when chlamydial EBs were pre-
incubated with bLf for 1 h or 3 h, indicating no direct effect of bLf
on C. trachomatis.
In contrast, bLf inhibited C. trachomatis entry into host cells, as
evidenced by a signiﬁcant reduction of chlamydial IFU observed
when HeLa-229 monolayers were pre-incubated with bLf for 1 or
3 h (1 h pre-incubation: P = 0.0008; 3 h pre-incubation: P = 0.00007)
(Figs. 1B and 1C). The inhibitory effect of bLf on C. trachomatis entry
was more pronounced when HeLa-229 cells were preincubated
with bLf for 3 h compared with 1 h (P = 0.0124) (Fig. 1C).
To further conﬁrm the inhibitory effect of bLf on C. trachomatis
entry into host cells, bLf was added at the moment of HeLa-229
monolayer infection with C. trachomatis. The presence of bLf dur-
ing the infection phase signiﬁcantly inhibited C. trachomatis entry
into HeLa-229 cells at the same extent evidenced when bLf was
pre-incubated with cell monolayers for 1 or 3 h (Figs. 1B, 1C, and
1D). To determine whether bLf inhibited chlamydial replication,
bLf was added after 3 h of C. trachomatis infection. The addition of
bLf under these experimental conditions resulted in no signif-
icant reduction of the number of intracellular chlamydial IFUs
(P = 0.28) (Fig. 1E).
Effect of lactoferrin on IL-6 and IL-8 cytokine production by
HeLa-229 cells infected with C. trachomatis
To investigate the effect of bLf on the inﬂammatory response,
HeLa-229 cells were infected with C. trachomatis at a MOI of 5, and
after 3 h of infection, bLf was added to the medium. Of note, the
addition of bLf at 3 h post-infection did not inﬂuence the intracel-
lular number of C. trachomatis infecting the cell monolayers at the
MOI of 0.05 (Fig. 1E) or at the MOI of 5 (data not shown), thus
allowing the detection of the actual synthesis of IL-6 and IL-8 by
the same number of intracellular C. trachomatis. The production of
IL-6 and IL-8 was evaluated in the supernatants (Figs. 2 and 3,
respectively). The treatment with bLf did not raise the cytokine
levels in noninfected cells compared with the cell monolayers
alone. On the contrary, the infection with C. trachomatis induced a
signiﬁcant increase of both IL-6 and IL-8 levels. The addition of bLf
to infected cells 3 h post-infection caused a signiﬁcant decrease of
both IL-6 and IL-8 levels compared with infected cells not treated
with bLF (P < 0.05). In particular, bLf signiﬁcantly decreased IL-6
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and IL-8 concentrations, even if cytokine levels remained higher
than those synthesized by noninfected cell monolayers.
Clinical trials
Among 198 pregnant women, we excluded 16 women affected
by bacterial vaginosis unrelated to C. trachomatis, and 6 women
for protocol violation. One hundred seventy-six pregnant women
completed the study and, among them, 7 asymptomatic pregnant
women, positive to C. trachomatis DFA and showing high concen-
tration of IL-6 in cervical ﬂuids, were treated with the intravaginal
administration of bLf (100 mg) every 8 h for 30 days.
After 1 month, 6 out of 7 cervical specimens were negative to
C. trachomatis DFA, and the cervical ﬂuids showed a decrease in
IL-6 concentration (frommean values of 250 ± 19 to 50 ± 11 pg/mL).
One out of 7 pregnant women was positive to C. trachomatis DFA
and cervical IL-6 levels did not decrease, ranging between about
Fig. 1. Inclusion forming units (IFU) of Chlamydia trachomatis observed by immunoﬂuorescence assay in HeLa-229 cells infected at a MOI of
0.05 in the absence or presence of bLf added at different time. (A) One hour preincubation of C. trachomatis EBs in the absence or presence of
bLf; (B) 1 h preincubation of HeLa-229 cells in the absence or presence of bLf; (C) 3 h preincubation of HeLa-229 cells in the absence or
presence of bLf; (D) HeLa-229 cells infected with C. trachomatis and treated with bLf; (E) Addition of bLf to HeLa-229 cells at 3 h.p.i. with
C. trachomatis.
Fig. 2. IL-6 levels in the supernatants of HeLa-229 cell cultures after 48 h of incubation. The infection was performed at a MOI of 5, and bLf
was added 3 h post-infection. The IL-6 concentrations are mean values ± SD. A value for P < 0.05 was considered statistically signiﬁcant.
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270 and 300 pg/mL (Table 1). This patient was treated with antibi-
otics.
No maternal and neonatal side effects by bLf intravaginal ad-
ministration were observed.
Discussion
Some mucosal pathogenic bacteria are not only capable of ad-
hering but also of entering into nonprofessional phagocytes such
as epithelial cells. Inside host cells, bacteria are in a protective
niche in which they can replicate and persist, thus avoiding host
defences. In addition, antibiotic therapies are not always effective
in the eradication of intracellular pathogens (Armstead and Li
2011).
Chlamydia trachomatis is an obligate, intracellular pathogen re-
sponsible for the most common sexually transmitted bacterial
disease worldwide, causing acute and chronic infections. Unlike
acute infections, which can be cured with oral or topical admin-
istration of antibiotics, chronic infections are difﬁcult to eradi-
cate and need prolonged therapies, thus increasing the risk of
developing antibiotic resistance (Kohlhoff andHammerschlag 2015).
Therefore, novel alternative therapies are needed (Sessa et al.
2015). The difﬁculty in ﬁnding new agents against C. trachomatis
infection resides in the complex life-cycle of this peculiar patho-
gen. In fact, C. trachomatis has a unique biphasic developmental
cycle, alternating between the extracellular infectious EBs, meta-
bolically inactive, and the intracellular non-infectious RBs, which
are metabolically active. Of note, intracellular bacterial pathogens
require intracellular nutrients, including iron, for replication in
mammalian cells, and chlamydiae are no exception (Raulston 1997).
Concerning the ﬁrst phase of C. trachomatis infection, classical
antibacterial drugs are ineffective because EBs are metabolically
inactive.
Conversely, antibacterial drugs could be active against intracel-
lular replicative RBs, since they aremetabolically active. However,
antibacterial drugs cannot usually enter host cells.
A further key issue is represented by the intracellular rediffer-
entiation of RBs (after intracellular replication) into EBs, which
are released following the lysis of host cells, ready to infect neigh-
boring epithelial cells and, hence, perpetuate the infectious pro-
cess (Belland et al. 2003).
Therefore, an ideal drug against C. trachomatis infection should:
• inhibit adhesion and entry of C. trachomatis EBs into host cells;
• inhibit intracellular replication of C. trachomatis RBs;
• inhibit the reinfection of host cells by EBs, extracellularly re-
leased after the redifferentiation of RBs into EBs.
Lf is thought to play a pivotal role in the prevention of infec-
tions. Its ability to sequester iron from potential pathogens is
considered an important feature to combat infections. Moreover,
its cationic charge is responsible for the binding to bacterial and
Table 1. General characteristics of pregnantwomen positive
for Chlamydia trachomatis before and after intravaginal ad-
ministration of lactoferrin (100 mg every 8 h/day).
Before
treatment
After
treatment
n = 6
C. trachomatis DFA Positive Negative
Mean values for cervical IL-6 (pg/mL) 250±19 50±11
Spontaneous delivery (week) 39–40 —
Mean values of birth weight (g) 3727±175 —
Apgar scores 9/10 —
n = 1
C. trachomatis DFA Positive Positive
Cervical IL-6 (pg/mL) 263 285
Caesarean section (week) 39 —
Birth weight (g) 3378 —
Apgar scores 9 —
Note: n, number of pregnant women; DFA, direct immunoﬂuores-
cence assay.
Fig. 3. IL-8 levels in the supernatants of HeLa-229 cell cultures after 48 h of infection. The infection was performed at a MOI of 5, and bLf was
added 3 h post-infection. The IL-8 concentrations are mean values ± SD. A value of P < 0.05 was considered statistically signiﬁcant.
Pagination not final (cite DOI) / Pagination provisoire (citer le DOI)
Sessa et al. 5
Published by NRC Research Press
B
io
ch
em
. C
el
l B
io
l. 
D
ow
nl
oa
de
d 
fro
m
 w
w
w
.n
rc
re
se
ar
ch
pr
es
s.c
om
 b
y 
Pr
of
es
so
r P
ie
ra
 V
al
en
ti 
on
 0
1/
25
/1
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
 
cell surface components (Valenti and Antonini 2005). This Lf prop-
erty has been shown to inhibit adhesion and entry into epithelial
cells of several facultative intracellular bacteria (Longhi et al.
1993; Ajello et al. 2002; Di Biase et al. 2004; Willer et al. 2004;
Berlutti et al. 2008); however, Lf activity against obligate intracel-
lular bacteria as C. trachomatis has never been observed.
In this study, we utilized a preparation of bLf, iron -saturated at
20%, to consent further iron chelation, an essential nutrient for
C. trachomatis developmental cycle (Raulston 1997). In fact, in the
absence of free, available iron, C. trachomatis enters into a persis-
tent state, as evidenced by the addition of iron-chelating agents,
such as deferoxamine mesylate (DFO) or 2,2=-bipyridyl (Bpdl) to
C. trachomatis infected cell monolayers, leading to small-sized
inclusions containing enlarged, aberrant and nondividing RBs
(ThompsonandCarabeo2011), unable togenerate infectiousprogeny
(Wyrick 2010).
Different from data reported by Thompson and Carabeo (2011),
we found that the addition of bLf to HeLa cell monolayers 3 h
post-infection resulted in no signiﬁcant reduction of the number
of intracellular chlamydial IFU (P = 0.28) (Fig. 1E) and of infectious
progeny. These conﬂicting data could be due to the higher effec-
tive concentrations of iron-chelating agents (from 100 to 200mol/L)
(Thompson and Carabeo 2011) compared with 1.25 mol/L bLf,
corresponding to 2.5 mol/L iron binding sites, used in this study.
We believe it is very interesting that bLf does not affect either
the replication of RBs or the induction of aberrant RBs, thus avoid-
ing the “silent” reservoir that leads to chronic infection and in-
ﬂammation.
In fact, aberrant RBs can contribute to chronic inﬂammation
(although this aspect is still under debate). Of note, recurrent
chlamydial disease may also result from the persistence of the
microorganism after unresolved infections (Wyrick 2010).
To the best of our knowledge, we have demonstrated for the
ﬁrst time that the incubation of cell monolayers with bLf before
the infection or at the moment of the infection signiﬁcantly in-
hibited the adhesion and entry of C. trachomatis into epithelial
cells. Therefore, the inhibition of C. trachomatis infectivity by bLf
was dependent on its interaction with the cell surface. Moreover,
bLf could bind to cell surface glycosaminoglycans as well as to
heparan sulfate proteoglycans (Wu et al. 1995; Lang et al. 2011),
which are potential receptors for C. trachomatis adhesion (Stallmann
and Hegemann 2015).
Conversely, the preincubation of bLf with C. trachomatis did not
inﬂuence its infectivity, supporting the idea that the speciﬁc in-
teraction between bLf and epithelial host cells seems to be the sole
pivotal mechanism responsible for the inhibition of C. trachomatis
invasion.
Similar to the results obtained in epithelial cell monolayers
infected with other facultative intracellular pathogens (Berlutti
et al. 2006; Valenti et al. 2011; Frioni et al. 2014), the addition of bLf
signiﬁcantly decreased the IL-8 and IL-6 levels synthetized by
C. trachomatis infected cells. To avoid the possibility that the IL-8
and IL-6 decrease was related to the different number of C. trachomatis
IFUs, these experiments were carried out by adding bLf 3 h post-
infection. These results demonstrated once again the ability of bLf
to down-regulate pro-inﬂammatory cytokine synthesis. Although
it has been known for years that exogenous Lf localized to cell
nucleus (Ashida et al. 2004; Suzuki et al. 2008; Valenti et al. 2011),
the mechanisms by which bLf could perform its anti-inﬂammatory
activity are still under debate.
These in-vitro results, showing for the ﬁrst time the protective
effects of bLf against C. trachomatis infection, led us to investigate
its efﬁcacy also in asymptomatic pregnant women positive to
C. trachomatis and with high levels of IL-6 in cervical ﬂuids.
Seven out of 176 pregnant women enrolled in this pilot study,
showing cervical specimens positive to C. trachomatis, were treated
with the intravaginal administration of bLf (100 mg) every 8 h for
30 days.
After 1 month, 6 pregnant women tested negative for C. trachomatis
and showed decreased IL-6 levels in their cervical ﬂuids (from
mean values of 250 ± 19 to 50 ± 11 pg/mL).
Similar to what we observed in the in-vitro model, intravaginal
administration of bLf seems to act by protecting host cells against
the adhesion and entry of chlamydial EBs, which are released
extracellularly after redifferentiation of RBs to EBs. The simulta-
neous decrease of IL-6 levels could be a marker for the lack of
reinfection by C. trachomatis EBs in the presence of bLf.
Even if other clinical trials are required, the protective effect of
bLf against C. trachomatis, demonstrated for the ﬁrst time in this
study, suggests a further therapeutic approach based on its intra-
vaginal administration in addition to that already reported in
preventing and curing the preterm delivery (Paesano et al. 2012).
Acknowledgement
This study was supported by Sapienza University for both R.S.
and P.V.
References
Ajello, M., Greco, R., Giansanti, F., Massucci, M.T., Antonini, G., and Valenti, P.
2002. Anti-invasive activity of bovine lactoferrin towards group A strepto-
cocci. Biochem. Cell Biol. 80(1): 119–124. doi:10.1139/o01-211. PMID:11908635.
Al-Younes, H.M., Rudel, T., Brinkmann, V., Szczepek, A.J., and Meyer, T.F. 2001.
Low iron availability modulates the course of Chlamydia pneumoniae infec-
tion. Cell. Microbiol. 3(6): 427–437. doi:10.1046/j.1462-5822.2001.00125.x.
PMID:11422085.
Apgar, V. 1953. A proposal for a new method of evaluation of the newborn
infant. Curr. Res. Anesth. Analg. 32(4): 260–267. PMID:13083014.
Armstead, A.L., and Li, B. 2011. Nanomedicine as an emerging approach against
intracellular pathogens. Int. J. Nanomed. 6: 3281–3293. PMID:22228996.
Ashida, K., Sasaki, H., Suzuki, Y.A., and Lönnerdal, B. 2004. Cellular internaliza-
tion of lactoferrin in intestinal epithelial cells. BioMetals, 17(3): 311–315. doi:
10.1023/B:BIOM.0000027710.13543.3f. PMID:15222483.
Bastidas, R.J., Elwell, C.A., Engel, J.N., and Valdivia, R.H. 2013. Chlamydial intra-
cellular survival strategies. Cold Spring Harb. Perspect. Med. 3(5): a010256.
doi:10.1101/cshperspect.a010256. PMID:23637308.
Belland, R.J., Zhong, G., Crane, D.D., Hogan, D., Sturdevant, D., Sharma, J., et al.
2003. Genomic transcriptional proﬁling of the developmental cycle of
Chlamydia trachomatis. Proc. Natl. Acad. Sci. U.S.A. 100(14): 8478–8483. doi:10.
1073/pnas.1331135100. PMID:12815105.
Berlutti, F., Schippa, S., Morea, C., Sarli, S., Perfetto, B., Donnarumma, G., and
Valenti, P. 2006. Lactoferrin downregulates pro-inﬂammatory cytokines up-
expressed in intestinal epithelial cells infected with invasive or noninvasive
Escherichia coli strains. Biochem. Cell Biol. 84(3): 351–357. doi:10.1139/o06-039.
PMID:16936806.
Berlutti, F., Superti, F., Nicoletti, M., Morea, C., Frioni, A., Ammendolia, M.G.,
et al. 2008. Bovine lactoferrin inhibits the efﬁciency of invasion of respiratory
A549 cells of different iron-regulated morphological forms of Pseudomonas
aeruginosa and Burkholderia cenocepacia. Int. J. Immunopathol. Pharmacol.
21(1): 51–59. PMID:18336731.
Di Biase, A.M., Tinari, A., Pietrantoni, A., Antonini, G., Valenti, P., Conte, M.P.,
and Superti, F. 2004. Effect of bovine lactoferricin on enteropathogenic
Yersinia adhesion and invasion in HEp-2 cells. J. Med. Microbiol. 53(5): 407–
412. doi:10.1099/jmm.0.05410-0. PMID:15096550.
Di Pietro, M., Filardo, S., De Santis, F., and Sessa, R. 2013. New insights into
Chlamydiae persistence: an energy metabolism strategy? Int. J. Immuno-
pathol. Pharmacol. 26(2): 525–528. PMID:23755769.
Frioni, A., Conte, M.P., Cutone, A., Longhi, C., Musci, G., di Patti, M.C., et al. 2014.
Lactoferrin differently modulates the inﬂammatory response in epithelial
models mimicking human inﬂammatory and infectious diseases. BioMetals,
27(5): 843–856. doi:10.1007/s10534-014-9740-9. PMID:24770943.
Hogan, R.J., Mathews, S.A., Mukhopadhyay, S., Summersgill, J.T., and Timms, P.
2004. Chlamydial persistence: beyond the biphasic paradigm. Infect. Immun.
72(4): 1843–1855. doi:10.1128/IAI.72.4.1843-1855.2004. PMID:15039303.
Kohlhoff, S.A., and Hammerschlag, M.R. 2015. Treatment of Chlamydial infec-
tions: 2014 update. Expert Opin. Pharmacother. 16(2): 205–212. doi:10.1517/
14656566.2015.999041. PMID:25579069.
Lang, J., Yang, N., Deng, J., Liu, K., Yang, P., Zhang, G., and Jiang, C. 2011. Inhibi-
tion of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate
proteoglycans. PLoS One, 6(8): e23710. doi:10.1371/journal.pone.0023710.
PMID:21887302.
Longhi, C., Conte, M.P., Seganti, L., Polidoro, M., Alfsen, A., and Valenti, P. 1993.
Inﬂuence of lactoferrin on the entry process of Escherichia coli HB101 (pRI203)
in HeLa cells. Med. Microbiol. Immunol. 182(1): 25–35. PMID:8497210.
Masson, P.L., Heremans, J.F., and Schonne, E. 1969. Lactoferrin, an iron-binding
protein in neutrophilic leukocytes. J. Exp. Med. 130(3): 643–658. doi:10.1084/
jem.130.3.643. PMID:4979954.
Mastromarino, P., Di Pietro, M., Schiavoni, G., Nardis, C., Gentile, M., and
Pagination not final (cite DOI) / Pagination provisoire (citer le DOI)
6 Biochem. Cell Biol. Vol. 00, 0000
Published by NRC Research Press
B
io
ch
em
. C
el
l B
io
l. 
D
ow
nl
oa
de
d 
fro
m
 w
w
w
.n
rc
re
se
ar
ch
pr
es
s.c
om
 b
y 
Pr
of
es
so
r P
ie
ra
 V
al
en
ti 
on
 0
1/
25
/1
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
 
Sessa, R. 2014. Effects of vaginal lactobacilli in Chlamydia trachomatis infec-
tion. Int. J. Med. Microbiol. 304(5–6): 654–661. doi:10.1016/j.ijmm.2014.04.
006. PMID:24875405.
Newman, L., Rowley, J., Vander Hoorn, S., Wijesooriya, N.S., Unemo, M., Low, N.,
et al. 2015. Global estimates of the prevalence and incidence of four curable
sexually transmitted infections in 2012 based on systematic review and global
reporting. PLoS One, 10(12): e0143304. doi:10.1371/journal.pone.0143304. PMID:
26646541.
Paesano, R., Pietropaoli, M., Berlutti, F., and Valenti, P. 2012. Bovine lactoferrin
in preventing preterm delivery associated with sterile inﬂammation. Biochem.
Cell Biol. 90(3): 468–475. doi:10.1139/o11-060. PMID:22292525.
Puddu, P., Latorre, D., Carollo, M., Catizone, A., Ricci, G., Valenti, P., and
Gessani, S. 2011. Bovine lactoferrin counteracts Toll-like receptor mediated
activation signals in antigen presenting cells. PLoS One, 6(7): e22504. doi:10.
1371/journal.pone.0022504. PMID:21799877.
Raulston, J.E. 1997. Response of Chlamydia trachomatis serovar E to iron restric-
tion vitro and evidence for iron-regulated chlamydial proteins. Infect. Im-
mun. 65(11): 4539–4547. PMID:9353031.
Redgrove, K.A., and McLaughlin, E.A. 2014. The role of the immune response in
Chlamydia trachomatis infection of the male genital tract: a double-edged
sword. Front. Immunol. 5: 534. doi:10.3389/ﬁmmu.2014.00534. PMID:25386180.
Sessa, R., Di Pietro, M., De Santis, F., Filardo, S., Ragno, R., and Angiolella, L. 2015
Effects ofMentha suaveolens essential oil on Chlamydia trachomatis. BioMed Res.
Int. 2015: 508071. doi:10.1155/2015/508071. PMID:25685793.
Shaw, K., Coleman, D., O’Sullivan, M., and Stephens, N. 2011. Public health
policies and management strategies for genital Chlamydia trachomatis infec-
tion. Risk Manage. Healthc. Policy, 4: 57–65. doi:10.2147/RMHP.S12710. PMID:
22312228.
Stallmann, S., and Hegemann, J.H. 2015. The Chlamydia trachomatis Ctad1 invasin
exploits the human integrin 1 receptor for host cell entry. Cell. Microbiol.
doi:10.1111/cmi.12549.
Suzuki, Y.A., Wong, H., Ashida, K.Y., Schryvers, A.B., and Lönnerdal, B. 2008. The
N1 domain of human lactoferrin is required for internalization by CaCo-2
cells and targeting to the nucleus. Biochemistry, 47(41): 10915–10920. doi:10.
1021/bi8012164. PMID:18785755.
Thompson, C.C., and Carabeo, R.A. 2011. An optimalmethod of iron starvation of
the obligate intracellular pathogen, Chlamydia trachomatis. Front. Microbiol.
2: 20. doi:10.3389/fmicb.2011.00020. PMID:21687412.
Valenti, P., and Antonini, G. 2005. Lactoferrin: an important host defence
against microbial and viral attack. Cell. Mol. Life Sci. 62(22): 2576–2587.
doi:10.1007/s00018-005-5372-0. PMID:16261253.
Valenti, P., Catizone, A., Pantanella, F., Frioni, A., Natalizi, T., Tendini, M., and
Berlutti, F. 2011. Lactoferrin decreases inﬂammatory response by cystic ﬁbro-
sis bronchial cells invaded with Burkholderia cenocepacia iron-modulated bio-
ﬁlm. Int. J. Immunopathol. Pharmacol. 24(4): 1057–1068. PMID:22230411.
Valore, E.V., Park, C.H., Igreti, S.L., and Ganz, T. 2002. Antimicrobial compo-
nents of vaginal ﬂuid. Am. J. Obstet. Gynecol. 187(3): 561–568. doi:10.1067/
mob.2002.125280. PMID:12237628.
Willer, E.M., Lima, R.L., and Giugliano, L.G. 2004. In vitro adhesion and invasion
inhibition of Shigella dysenteriae, Shigella ﬂexneri and Shigella sonnei clinical
strains by human milk proteins. BMC Microbiol. 4: 18. doi:10.1186/1471-2180-
4-18. PMID:15115555.
Workowski, K.A., and Bolan, G.A. 2015. Sexually transmitted diseases treatment
guidelines, 2015. CDC, Morbidity and Mortality Weekly Report, Recommen-
dations and Reports, 64(RR-3): 1–137.
Wu, H.F., Monroe, D.M., and Church, F.C. 1995. Characterization of the
glycosaminoglycan-binding region of lactoferrin. Arch. Biochem. Biophys.
317(1): 85–92. doi:10.1006/abbi.1995.1139. PMID:7872808.
Wyrick, P.B. 2010. Chlamydia trachomatis persistence in vitro: an overview.
J. Infect. Dis. 201(Suppl. 2): S88–S95. doi:10.1086/652394. PMID:20470046.
Pagination not final (cite DOI) / Pagination provisoire (citer le DOI)
Sessa et al. 7
Published by NRC Research Press
B
io
ch
em
. C
el
l B
io
l. 
D
ow
nl
oa
de
d 
fro
m
 w
w
w
.n
rc
re
se
ar
ch
pr
es
s.c
om
 b
y 
Pr
of
es
so
r P
ie
ra
 V
al
en
ti 
on
 0
1/
25
/1
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
 
